Stereotactic ablative body radiotherapy (SABR) is recommended to be available as a routinely commissioned treatment option for adults with localised, non-metastatic T1b, N0, M0 renal cancer and who are medically unfit for surgery within the criteria set out in this document.

The policy is restricted to certain age groups (adults) as there is insufficient evidence to confirm safety in those age groups not included in the proposition.